Pixium Vision (PAR: PIX)

Last close As at 24/05/2024

EUR0.15

−0.04 (−21.05%)

Market capitalisation

EUR1m

Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for Dry-ARMD. The company has completed a human feasibility study for Prima in Europe and expects to start implantations in a US feasibility study in H119.

Latest Insights

View More

Healthcare | Flash note

Pixium Vision — Safeguard proceedings underway

Healthcare | Update

Pixium Vision — Shareholder loan extends runway

Healthcare | Flash note

Pixium Vision — Breakthrough designation provides validation

Pixium-Vision_resized

Sector

Healthcare

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (6.9) (92.8) (97.1)
Relative (13.0) (92.8) (97.3)
52 week high/low €0.2/€0.0

Financials

Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX) and Treatt (TET). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via website

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 2.7 (9.7) (10.9) (23.06) N/A N/A
2022A 2.0 (11.5) (10.3) (21.09) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Research

Update

Healthcare

Pixium Vision — Moving ahead as expected

edison tv

Healthcare

Pixium Vision – executive interview

edison tv

Healthcare

Pixium Vision – Edison Open House interview

Flash note

Healthcare

Pixium Vision — H120 results broadly in line

Update

Healthcare

Pixium Vision — €7.3m capital increase completed

Outlook

Healthcare

Pixium Vision — Restoring eyesight in advanced Dry-AMD

Update

Healthcare

Pixium Vision — US feasibility study now underway

Flash note

Healthcare

Pixium Vision — Pixium appoints new CEO

Outlook

Healthcare

Pixium Vision — Prima gearing up for a pivotal year

Update

Healthcare

Pixium Vision — Financials in line as Prima advances

research

Healthcare

Pixium Vision — Financials in line as Prima advances

Flash note

Healthcare

Pixium Vision — Positive interim six-month Prima data

Flash note

Healthcare

Pixium Vision — Forfait Innovation decision postponed

Flash note

Healthcare

Pixium Vision — Update 12 January 2017

Update

Healthcare

Pixium Vision — Update 19 October 2016

Update

Healthcare

Pixium Vision — Update 27 July 2016

Update

Healthcare

Pixium Vision — Update 15 July 2016

Update

Healthcare

Pixium Vision — Update 24 February 2016

Update

Healthcare

Pixium Vision — Update 7 January 2016

Initiation

Healthcare

Pixium Vision — Update 22 September 2015

Further insights

insight

Healthcare

Retinal implants

thematic

Healthcare

Machine learning in drug development

cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?